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of this factor may provide insights into
the pathogenesis of CIU/CSU.
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TO THE EDITOR
Accurate diagnosis of melanoma is valu-
able in reducing melanoma mortality
and morbidity. A number of candidate
biomarkers have been developed for
melanoma (Mandala and Massi, 2014);
however, none has been accepted as
being accurate, easily interpretable, and
practical in diagnosing histologi-
cally challenging melanocytic lesions.
Recently, it was found that primary cilia
exist in melanocytes and melanoma
cells and that primary cilia were fre-
quently lost in melanomas (Kim et al.,
2011; Le Coz et al., 2014), suggesting
that the primary cilium may be used as a
biomarker for melanoma. However, it
remained unclear whether the loss of
cilia in melanoma was due to increased
proliferation or cell cycle progression.
The statistical power of using primary
cilium as a biomarker also remained to
be established.
Here, we independently evaluated
primary cilia by immunofluorescence
microscopy on 87 cases of melanocytic
nevi and melanomas obtained from the
archival collections of the Department
of Pathology of Stony Brook Medicine
between 2003 and 2011. This study was
approved by the IRB of Stony Brook
University. ARL13B (Proteintech, Chicago,
IL), acetylated a-tubulin (Sigma, St. Louis,
MO), and ACIII (Santa Cruz Biotechnol-
ogy, Dallas, TX) were used to detect
primary cilia; gamma-tubulin and chibby
(CBY1, (Takemaru et al., 2003)) were used
to detect basal body; SOX10 (Santa Cruz
Biotechnology) and S100 (BioCare
Medical, Concord, CA) were used to
detect melanocytes and melanoma cells,
as described previously (Dai et al., 2011).
Comparable results were obtained from all
antibodies of each category (Supple-
mentary Figure S1 and S2 online). An
average of 366 (97–959) cells were eval-
uated for each specimen.
Remarkable decrease in ciliated cells
was found in all types of melanoma
when compared with nevi. Specifically,
24.85±6.33% of melanocytes in nevi
were ciliated (Figure 1a). In contrast,
percentages of ciliated cells were reduced
to 4.36±2.13, 2.85±2.43, and 1.16±
0.70% in melanoma in situ, primary
melanoma, and metastatic melanoma,
respectively (Figure 1b–d). The decrease
was statistically significant (P¼ 2.50
10 17 by two-way analysis of variance;
Figure 1e). In comparison with nevi, all
types of melanoma demonstrated a
highly significant reduction in ciliated
cells (Po1109 by the Tukey test).
Proliferating cells typically show
higher rates of cilia formation comparedAccepted article preview online 28 January 2015; published online 26 February 2015
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Figure 1. Primary cilia are frequently lost in melanoma. (a–d) Primary cilia and melanocytes/melanoma cells were labeled with ARL13B (green) and SOX10 (red),
respectively, in compound dysplastic nevus (a), melanoma in situ (b), primary melanoma (c), and metastatic melanoma (d). (e) Ciliated SOX10-positive cells
expressed as a mean±SD. Two-way analysis of variance, P¼ 2.50 10 17. ‘‘**’’ represent statistical significance when compared with nevi (the Tukey test,
P¼ 1.01 10 9, 5.34 10 13, 5.21 10 13, respectively). Samples were analyzed independently by two investigators with similar results. Results obtained by
one investigator are presented. (f) Ciliated Ki67-negative melanocytes/melanoma cells. ‘‘*’’ represents statistical significance when compared with nevi (the Tukey
test, Po0.002). Scale bar¼20mm.
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Figure 2. Loss of primary cilia in melanoma cell lines. (a–c) Immunofluorescence labeling of primary cilia and basal bodies with ARL13B (NeuroMab) and
g-tubulin (Abcam), respectively, after 2-day serum-starvation. (d) Percentage of ciliated melanocytes, primary melanoma cells (WM115 and WM278), and
metastatic melanoma cells (WM266-4 and WM1617). Metastatic melanoma cells contained significantly reduced percentages of ciliated cells when compared
with paired primary melanoma cells (WM115 and WM278; P¼0.0009 and 0.0025, respectively). (e) Percentage of G0/G1 cells by propidium iodide staining after
2-day serum-starvation. Shaded areas represent proportions of ciliated cells in percentage. (f) Percentage of cells with basal body as determined by
g-tubulin and chibby. (g) Length of ciliary axoneme determined after 2-day serum starvation. Scale bar¼ 10mm.
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with nonproliferating cells (Ishikawa
and Marshall, 2011). To determine
whether the loss of cilia was a result of
increased proliferation, we examined
cilia in non-proliferating (Ki67-negative)
melanoma cells. A statistically significant
loss of primary cilia was observed in
non-proliferating melanoma cells
(Figure 1f and Supplementary Figure S3
online), suggesting that the loss of pri-
mary cilia in tumor cells was not a direct
result of proliferation.
To determine whether the loss of cilia
in tumor cells was caused by cell cycle
progression, we examined ciliogenesis
in two paired melanoma cell lines––i.e.,
cell lines derived from primary tumors
(WM115 and WM278) and metastatic
tumors (WM266-4 and WM1617,
respectively) of the same patients. Pri-
mary melanocytes (HEMn-LP) were
used as controls. Primary cilia and basal
bodies were immunolabeled with
ARL13B (NeuroMab, Davis, CA) and
g-tubulin (Abcam, Cambridge, MA),
respectively. An average of 1,829
(753–3,000) cells were evaluated for
each cell line. Two days after serum
starvation, HEMn-LP contained
62.00±3.51% ciliated cells; WM115
and WM278 contained 44.44±5.91%
and 55.44±10.08% ciliated cells,
whereas WM266-4 and WM1617 con-
tained significantly fewer ciliated cells
(7.56±2.04 and 0.00±0.00%, respec-
tively, Po6.910 5; Figure 2a–d). Inter-
estingly, after 2-day serum starvation, the
proportion of cells in G0/G1 were com-
parable among tumor cells (Figure 2e),
suggesting that the loss of primary cilia in
melanoma cells was unlikely a result of
cell cycle progression.
To gain insight into the mechanism
underlying the loss of cilia in melanoma
cells, we examined basal body forma-
tion and found that the presence of
basal body in serum-starved cells was
indistinguishable across all cell lines
(Figure 2f and Supplementary Figure S4
online). The length of the ciliary axo-
neme was also comparable among all
cell lines (Figure 2g). These observations
suggest that the loss of cilia is likely
intrinsic to melanoma cells. However,
the precise molecular mechanism
underlying reduced ciliogenesis or
increased ciliary retraction remains to
be determined.
Primary cilia perform diverse biologi-
cal functions (Satir et al., 2010; Oh and
Katsanis, 2012). The functions of pri-
mary cilia in melanocytes and mela-
noma cells are unknown. Defining the
functions of primary cilia in melanocytic
cells will undoubtedly contribute to
our understanding of whether loss of
primary cilia in melanoma is causative,
concomitant, or consequential to mali-
gnant transformation or invasion.
Because of the pivotal role of primary
cilia in hedgehog signaling (Singla
and Reiter, 2006; Goetz and Anderson,
2010), it will be interesting to determine
whether therapeutic potential of inhibit-
ing the hedgehog signaling pathway,
such as previously reported (Stecca
et al., 2007; Jalili et al., 2013), is depen-
dent on the presence of primary cilia in
melanoma cells. Correlating primary cilia
formation with mutations in the BRAF,
PTEN, and NRAS genes may also shed
light on the value of using primary cilia to
inform melanoma risk or survival.
In summary, this study demonstrated
that the loss of primary cilia is strongly
correlated with melanoma. Statistical
significance demonstrated the potential
of using primary cilium as a biomarker
for melanoma. Data obtained herein also
suggested that the loss of cilia in mela-
noma is unlikely caused by increased
proliferation, cell cycle progression, or
the absence of basal body. Further inves-
tigation on the molecular mechanism
underlying loss of primary cilia in mela-
noma may help understand malignant
transformation and invasion and identify
novel therapeutic avenues to reduce mel-
anoma-related morbidity and mortality.
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